The TGF-beta - SMAD pathway is inactivated in cronic lymphocytic leukemia cells.

Related Articles

The TGF-beta - SMAD pathway is inactivated in cronic lymphocytic leukemia cells.

Exp Oncol. 2017 Dec;39(4):286-290

Authors: Matveeva A, Kovalevska L, Kholodnyuk I, Ivanivskaya T, Kashuba E

Abstract
AIM: To study the status of the tumor growth factor beta (TGFB) pathway in chronic lymphocytic leukemia (CLL) cells and to uncover molecular details underlying CLL cell genesis.
OBJECTS AND METHODS: The study was conducted on peripheral blood samples of patients with CLL using the following methods: RNA isolation, analysis of expression of transcription factors using RT2 profiler assay, bioinformatics analysis of publicly available data bases on expression.
RESULTS: We have shown that the TGFB - SMAD canonical pathway is not active in CLL cells. SMAD-responsive genes, such as BCL2L1 (BCL-XL), CCND2 (Cyclin D2), and MYC, are down-regulated in CLL cells compared with peripheral blood B cells of healthy donors.
CONCLUSIONS: The TGFB-mediated signaling is not active in CLL cells due to low (or absent) expression of SMAD1, -4, -5, -9, and ATF-3. Expression and phosphorylation status of SMAD2 and -3 should be further elucidated in the future studies.

PMID: 29284776 [PubMed - in process]

http://ift.tt/2DzHQgH